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Abstract 
Reperfusion as a therapeutic intervention for acute myocardial infarction-induced cardiac injury itself induces 
further cardiomyocyte death. β-arrestin (βarr)-biased β-adrenergic receptor (βAR) activation promotes 
survival signaling responses in vitro; thus, we hypothesize that this pathway can mitigate cardiomyocyte death 
at the time of reperfusion to better preserve function. However, a lack of efficacious βarr-biased orthosteric 
small molecules has prevented investigation into whether this pathway relays protection against ischemic injury 
in vivo. We recently demonstrated that the pepducin ICL1-9, a small lipidated peptide fragment designed from 
the first intracellular loop of β2AR, allosterically engaged pro-survival signaling cascades in a βarr-dependent 
manner in vitro. Thus, in this study we tested whether ICL1-9 relays cardioprotection against 
ischemia/reperfusion (I/R)-induced injury in vivo. 
Methods: Wild-type (WT) C57BL/6, β2AR knockout (KO), βarr1KO and βarr2KO mice received 
intracardiac injections of either ICL1-9 or a scrambled control pepducin (Scr) at the time of ischemia (30 min) 
followed by reperfusion for either 24 h, to assess infarct size and cardiomyocyte death, or 4 weeks, to monitor 
the impact of ICL1-9 on long-term cardiac structure and function. Neonatal rat ventricular myocytes (NRVM) 
were used to assess the impact of ICL1-9 versus Scr pepducin on cardiomyocyte survival and mitochondrial 
superoxide formation in response to either serum deprivation or hypoxia/reoxygenation (H/R) in vitro and to 
investigate the associated mechanism(s).  
Results: Intramyocardial injection of ICL1-9 at the time of I/R reduced infarct size, cardiomyocyte death and 
improved cardiac function in a β2AR- and βarr-dependent manner, which led to improved contractile function 
early and less fibrotic remodeling over time. Mechanistically, ICL1-9 attenuated mitochondrial superoxide 
production and promoted cardiomyocyte survival in a RhoA/ROCK-dependent manner. RhoA activation could 
be detected in cardiomyocytes and whole heart up to 24 h post-treatment, demonstrating the stability of 
ICL1-9 effects on βarr-dependent β2AR signaling.  
Conclusion: Pepducin-based allosteric modulation of βarr-dependent β2AR signaling represents a novel 
therapeutic approach to reduce reperfusion-induced cardiac injury and relay long-term cardiac remodeling 
benefits. 
Key words: Pepducin, β-arrestin, β2-adrenergic receptor, cardiac ischemia/reperfusion, cardiomyocyte 
Introduction 
Reperfusion has substantially reduced patient 
mortality following acute cardiac ischemic events, 
such as myocardial infarction (MI), but still induces 
oxidative damage and further cardiomyocyte death, 
contributing to ongoing risk of recurrent MI, sudden 
death, heart failure, and stroke [1-3]. Thus, current 
drug discovery efforts focus on mitigating 
cardiomyocyte death via engagement of pro-survival 
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signaling pathways or inhibition of cardiotoxic 
signaling events at the time of reperfusion. G 
protein-coupled receptors (GPCRs) constitute the 
largest class of drug targets, are expressed abundantly 
in the heart and have been mainstays of therapeutic 
investigation for the last two decades. β-adrenergic 
receptors (βARs) in particular play critical roles in the 
regulation of cardiac function and remodeling in 
response to acute ischemic injury, classically via G 
protein-dependent signaling. Both β1AR and β2AR 
are expressed in cardiomyocytes and although βAR 
stimulation has been shown capable of engaging 
pro-survival signaling pathways in cardiomyocytes, 
including epidermal growth factor receptor (EGFR), 
extracellular-regulated kinase 1/2 (ERK1/2) and Akt 
activation [4, 5], β1AR has also been shown to relay 
cardiomyocyte death in response to ischemic injury 
through either protein kinase A (PKA) or 
Ca2+/calmodulin-dependent protein kinase II 
(CAMKII) signaling [6, 7]. While β-blockers are used 
as a standard therapy post-infarction to reduce 
recurrent MI or sudden death [3], the development of 
pharmacologic tools that can differentially engage 
proximal βAR isoform-specific signaling pathways at 
the time of injury to promote cardioprotection and 
improve cardiac remodeling outcomes has been at the 
forefront of recent drug discovery efforts.  
It has been postulated for some time that 
proximal engagement of β-arrestin (βarr)-dependent 
βAR signaling in the absence of G protein activation 
has the capacity to impart survival benefits in 
cardiomyocytes [4, 5], but the ability to selectively 
engage this pathway with small molecules to mitigate 
I/R-induced myocyte death in vivo has been 
challenging. Pepducins, small lipidated peptide 
fragments designed from the amino acid sequences of 
the intracellular loop (ICL) domains of GPCRs, were 
originally shown to selectively engage proximal 
signaling events via allosteric modulation of 
protease-activated receptors [8]. Since their discovery, 
pepducins have been demonstrated capable of 
regulating an increasing cohort of GPCRs in a biased 
manner and have even begun to be tested in vivo [9]. 
Recently, we reported the development of 
β2AR-specific pepducins that selectively engage 
either G protein- or βarr-dependent pathways [10]. In 
particular, a cohort of pepducins based on the ICL1 
region of β2AR were shown in HEK 293 cells to 
induce βarr signaling, in the absence of G protein 
activation, the most potent of which was ICL1-9 [11].  
Subsequent analysis of ICL1-9 revealed that it 
increased the activation of EGFR and ERK1/2 in HEK 
293 cells and enhanced isolated adult cardiomyocyte 
contractility, independent of changes in canonical G 
protein-dependent signaling [11]. These results 
highlighted the ability of ICL1-9 to exert functional 
responses in cardiomyocytes and suggested that it 
may be capable of promoting cardiomyocyte survival 
signaling. Therefore, we sought to determine whether 
ICL1-9 confers cardioprotection against acute 
ischemic injury and identify the mechanism(s) by 
which such protection is mediated. Here, we show 
that intramyocardial injection of ICL1-9 administered 
at the time of injury reduces I/R-mediated infarct 
size, cardiomyocyte death and improves cardiac 
function acutely and long-term fibrotic remodeling. 
Further, we demonstrate that although the 
pro-survival effect of ICL1-9 in I/R-treated hearts is 
dependent upon β2AR and βarr1 or βarr2, the 
downstream survival signaling is mechanistically not 
relayed via EGFR, ERK1/2 or Akt, but is dependent 
instead upon the activation of RhoA. This is the first 
study to demonstrate the ability of a βarr-biased 
β2AR-selective allosteric modulator to promote 
cardiomyocyte survival signaling and impart 
structural and functional benefits following I/R, 
offering a novel therapeutic approach to reduce 
reperfusion-induced cardiac injury.  
Methods 
Experimental animals 
WT C57BL/6 mice as well as β2ARKO, βarr1KO 
and βarr2KO mice, all backcrossed onto a C57BL/6 
background, were used in this study (equal numbers 
male and female, randomly assigned to 
treatment/surgery groups, 8-12 weeks of age). 
Numbers of animals used per experimental condition 
are listed in figure legends. Animal procedures were 
performed in accordance with the Institutional 
Animal Care and Use Committee at Temple 
University and in accordance to the NIH Guidelines on 
the Use of Laboratory Animals. 
Intracardiac injection and 
ischemia/reperfusion (I/R) surgery 
Three evenly spaced injections (10 μL each at a 
concentration of 1 µg/µL) were administered into the 
left ventricle (LV) with either ICL1-9 
(Palm-TAIAKFERLQTVTNYFIT-NH2, Peptide 2.0 
Inc.) or scrambled (Scr) pepducin control 
(Palm-TTKYFQTINVLFAIRATE-NH2, Peptide 2.0 
Inc.). Pepducins were injected during needle 
retraction to enable their administration throughout 
the LV wall in both the remote zone and area at risk 
(AAR) of the LV. Injections occurred ~1 min prior to 
left coronary artery ligation. I/R injury was induced 
as previously described [12] with the surgeon blinded 
to the treatment groups. Briefly, mice were 
anesthetized via 2% isoflurane inhalation, a small skin 
incision was made and the pectoral muscles retracted 
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to expose the fourth intercostal space where a small 
hole was formed to pop out the heart. The left 
coronary artery was sutured ~2-3 mm from its origin 
with a slipknot and the heart was placed back into the 
intrathoracic space followed by closure of muscle and 
skin. Sham animals received the same surgical 
procedures without tying of the suture. After 30 min 
of ischemia, the slipknot was released to allow 
reperfusion of the myocardium. Animals received a 
single dose (0.3 mg/kg) of buprenorphine 
immediately following surgery.  
LV area at risk, infarct size and 
immunohistochemistry 
I/R-induced injury was detected by Evans 
blue/triphenyltetrazolium chloride (TTC) double 
staining. Hearts were excised after 24 h reperfusion 
and the ligature around the LCA was retied. Aortas 
were injected with 0.2 mL of 2% Evans blue dye and 
hearts were extracted and sliced into five 1.0 
mm-thick sections. The sections were incubated with 
1% TTC (Sigma) in phosphate buffered saline (PBS; 
pH 7.4) for 5 min at 37 °C. Slices were immediately 
imaged for infarct size using NIS Elements software 
for recording images and image analysis. Myocardial 
infarcts were imaged using NIS Elements software to 
measure the unstained portion (area at risk; AAR), the 
Evans blue-stained portion (area not at risk; ANAR), 
the TTC-stained area (red) and TTC-negative stained 
area (white; infarcted myocardium), expressed as a % 
of AAR. For Masson trichrome and Wheat germ 
agglutinin (WGA) staining, excised hearts were fixed 
in 4% paraformaldehyde, paraffin embedded and 
sectioned at 5 μm thickness. Deparaffinized sections 
were stained for Masson trichrome (Sigma-Aldrich) or 
wheat germ agglutinin (WGA, Vector Labs). An In 
Situ Cell Death Detection Kit, TMR Red (Roche 
Diagnostics; Mannheim, Germany) was used to 
measure cell death via the TUNEL (TdT-mediated 
dUTP-X nick end labeling) method in deparaffinized 
heart sections. Deparaffinized sections were 
incubated with proteinase K and DNA strand breaks 
were labeled according to the manufacturer’s 
instructions using tetra-methyl-rhodamine-dUTP. 
Hearts were counterstained with troponin I (TNNI, 
1:100; Cell Signaling; Danvers, MA) to identify 
cardiomyocytes. Cells were visualized at 20X 
magnification using a Nikon Eclipse microscope and 
TUNEL-positive cardiomyocytes were calculated in 
relation to the number of DAPI-stained 
cardiomyocyte nuclei from 10 random fields in the 
ANAR and AAR. 
Echocardiography 
Cardiac function was performed at baseline, 1, 3, 
7, 14, 21 and 28 days post-I/R via transthoracic 
two-dimensional echocardiography using a 
VisualSonics Vevo 2100 System with a 12 MHz probe 
on mice anesthetized with isoflurane (1.5%) and body 
temperature was maintained on a heated table with 
embedded ECG leads to monitor heart rate, 
temperature of the animal, electrocardiogram and 
breathing. The parasternal short-axis views of the 
heart were obtained in B-mode by placing the 
transducer in the parasternal long-axis and rotating 
the transducer 90° in a clockwise fashion to find the 
parasternal short-axis. For measurements, M-mode 
echocardiography was performed in the parasternal 
short-axis view at the level of the papillary muscle to 
assess several cardiac parameters including left 
ventricular (LV) volumes and internal diameters (ID) 
in systole (s) and diastole (d), wall thickness, LV 
fractional shortening and ejection fraction. Percent 
fractional shortening was calculated using the 
equation (LVIDd – LVIDs) / LVIDd × 100%. Percent 
ejection fraction was calculated using the equation 
(LVvold – LVvols) / LVvold × 100%. The assessor was 
blinded to the groups and the data was compiled into 
treatment and surgical groups only after the analyses 
were completed.  
Primary neonatal rat ventricular myocyte 
(NRVM) isolation 
Primary neonatal cardiomyocytes were prepared 
from 1 to 2 day old Sprague Dawley rat pups (Harlan 
Laboratories; Indianapolis, IN) by manual and 
enzymatic digestion. Hearts were excised and placed 
in sterile ADS solution (116 mM NaCl, 20 mM HEPES, 
80 μM Na2HPO4, 56 mM glucose, 5.4 mM KCl, 80 mM 
MgSO4; pH 7.4). Blood and connective tissue were 
removed and the ventricles were minced and 
subjected to five 15 min enzymatic digestions using 
collagenase II (Worthington; Lakewood, NJ) and 
pancreatin. Myocytes and fibroblasts were separated 
via pre-plating for 2 h. NRVM were cultured 
overnight in F-10 media containing 10% horse serum, 
5% fetal bovine serum (FBS) and 1% PSF at 37 °C in a 
humidified incubator with 5% CO2. After 24 h, the 
media was replaced with F-10 media containing 5% 
FBS. At least 3 independent cell preparations were 
used per experimental condition.  
Radioligand binding 
The density of βAR on cardiac membranes, 
prepared as previously described [13], or NRVM were 
determined by saturation binding experiments. 
Cardiac membranes (25 μg of protein) or single cell 
suspensions (1×105 cells) of NRVM were incubated 
with [125I]-cyanopindolol ([125I]-CYP; 200 pM; 
PerkinElmer) in binding buffer (75 mM Tris, pH 7.4, 2 
mM EDTA, 12.5 mM MgCl2, 1 μg/mL aprotinin, 1 
μg/mL leupeptin). Incubations were performed in the 
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presence or absence of propranolol (10 μM) to 
determine non-specific binding of CGP20712A and 
ICI 118,551 (100 nM) to determine βAR subtype 
expression. Reactions were performed in a 250 μL 
volume and allowed to equilibrate at 37 °C for 1 h 
before filtering through a glass fiber filter (Whatman 
GF/C; Brandel). Each filter was washed five times 
with 5 mL of ice-cold wash buffer (10 mM Tris, pH 
7.4, 10 mM EDTA) to remove unbound drug. The 
amount of total and nonspecific radiolabel bound to 
cells was determined on a gamma counter and 
receptor density was normalized to cell number 
(NRVM) or protein amount (cardiac membranes). All 
assays were performed in duplicate. 
Caspase 3/7 activity assay and TUNEL 
measurements 
Caspase 3/7 activity was measured using a 
Caspase-Glo® 3/7 Assay according to the 
manufacturer’s instructions (Promega; Madison, WI). 
In brief, NRVM were plated at 10,000 cells/well in 
white-walled 96-well plates. Following stabilization in 
culture, cells underwent 3 h serum starvation 
followed by inhibitor pre-treatment: PD98059 (10 μM 
for 10 min), LY294002 (10 μM for 10 min), AG1478 (10 
μM for 10 min) or rhosin (10 μM for 1 h). NRVM were 
subsequently treated with Scr or ICL1-9 pepducin (10 
μM each) for 24 h and 100 μL Caspase-Glo® 3/7 
Reagent was added to each well. Plates were 
incubated for 1 h prior to reading luminescence. For 
TUNEL assays, NRVM were plated on 
fibronectin-coated glass-bottom dishes and 
underwent serum deprivation ± Scr or ICL1-9 
pepducin treatment with or without rhosin (10 µM 
each) for 24 h, following which they were fixed with 
4% paraformaldehyde and underwent staining with 
TUNEL (red) and DAPI (blue) as described above as 
well as α-sarcomeric actin (αSrA, green; 1:500 
overnight incubation (Sigma) followed by goat 
anti-mouse Alexa Fluor-488 1:1000 for 1 h 
(ThermoFisher)). Images were captured using a Zeiss 
Axio Observer Z1 fluorescent microscope with a 40X 
oil immersion lens. TUNEL-positive α-SrA-positive 
cardiomyocytes were calculated as a % of the total 
α-SrA-positive cardiomyocytes from 5 images per 
dish. 
Immunoblot analysis 
Heart samples or primary cardiomyocytes were 
homogenized in RIPA buffer containing 1X HALT 
protease inhibitor cocktail (78437; Thermo Scientific; 
Rockford, IL) and phosphatase inhibitor cocktail set 
IV (524628; Calbiochem, USA). Equal amounts of 
lysates were resolved by SDS-polyacrylamide gel 
electrophoresis (10% gels) and transferred to 
Immobilon-PSQ polyvinylidene fluoride 0.2 μm pore 
size membranes (Millipore; Billerica, MA). Odyssey 
Blocking Buffer (LI-COR Biosciences; Lincoln, NE) 
was used to prevent non-specific binding. 
Immunoblotting was performed overnight at 4 °C 
with diluted antibodies against phospho-ERK1/2 
(Cell Signaling), total ERK1/2 (1:5000; Cell signaling), 
phospho-Akt (1:1000; Cell Signaling), total-Akt 
(1:1000; Cell Signaling), RhoA (1:500; Cytoskeleton, 
Inc) or GAPDH (1:1000; Cell Signaling). After 
washing with TBS-T, membranes were incubated at 
room temperature for 60 min with the appropriate 
diluted secondary antibody (IRDye680 Donkey 
anti-rabbit IgG (H + L) at 1:20,000; IRDye800CW Goat 
anti-mouse IgG (H + L) at 1:15,000; LI-COR 
Biosciences; IRDye680 Donkey anti-goat IgG (H+L) at 
1:20,000). Bound antibody was detected using the 
LI-COR Biosciences Odyssey System (LI-COR 
Biosciences).  
RhoA activity assay 
Activated RhoA was determined using a RhoA 
Pull-Down Activation Assay Biochem Kit 
(Cytoskeleton, Inc) according to the manufacturer’s 
instructions. In brief, NRVM were washed with 
ice-cold PBS prior to lysis or hearts were 
homogenized in lysis buffer and centrifuged at 10,000 
×g for 1 min to clarify samples. Equal amounts of 
protein (1000 μg for NRVM and 3000 μg for hearts) 
were added to 15 μg GST-Rho binding domain (RBD) 
beads and incubated for 1 h at 4 °C. The beads were 
washed and boiled for 2 min at 95 °C in 2X Laemmli 
Buffer and samples separated by SDS-PAGE as 
described above. Precipitated GTP-bound RhoA was 
normalized to total RhoA and GAPDH in the whole 
cell lysate (100 µg loaded).  
In vitro hypoxia/reoxygenation (H/R) 
NRVM were pre-treated with ICI 118,551 (100 
nM for 10 min), Y-27632 (10 μM for 10 min) or rhosin 
(10 μM for 1 h) prior to treatment with Scr or ICL1-9 
pepducin (10 μM each). Cells were subjected to 
hypoxia in Hanks Balanced Salt Solution 
supplemented with 1 mM MgCl2, 2 mM CaCl2 and 10 
mM HEPES under 95% N2 and 5% CO2 at 37 °C for 4 h 
in the presence of inhibitors and pepducins. Cells 
were then changed to fresh culture medium (F-10 
media containing 5% FBS and 1% PSF) and cultured 
under normoxic conditions at 37 °C with 1% O2 and 
5% CO2 for 20 h.  
Mitochondrial superoxide production 
Mitochondrial superoxide production was 
measured using MitoSOX™ in NRVM. Cells were 
loaded for 10 min with 5 μM MitoSox™ in PBS with 
Ca2+ and Mg2+ at 37 °C. Cells were washed three times 
and counterstained with DAPI. Cells were imaged in 
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warm PBS with Ca2+ and Mg2+ at 100X magnification 
on a Nikon Eclipse microscope and fluorescence was 
calculated on a plate reader with excitation/emission 
of 510/580 nm. MitoSOX fluorescence was 
normalized to DAPI. 
Statistical analysis 
Data presented are expressed as mean ± 
standard error of the mean (SEM). Statistical analyses 
were performed using a two-tailed unpaired 
Student’s t-test, a one-way ANOVA with Tukey’s 
multiple comparison test or a two-way repeated 
measures ANOVA with Bonferroni post test as 
appropriate using Prism 5.0 software (GraphPad 
Software; San Diego, CA) with n and p values 
indicated in figure legends. No statistical differences 
were observed between male and female animals, 
thus all data is a combination of both sexes within 
treatment/surgical groups. 
Results 
ICL1-9 reduces cardiac injury after I/R  
To determine if direct cardiac administration of a 
pepducin results in sustained localization within the 
myocardium in vivo, we administered TMR-labeled 
ICL1-9 (ICL1-9TMR) via intracardiac injection and 
monitored its localization over time. Within 3 h of 
injection, ICL1-9TMR localized within or just 
proximal to the injection track; however, more diffuse 
localization distal to the injection site was observed at 
6 and 24 h (Figure 1A), both within cardiomyocytes 
and interstitially, but was largely undetectable by 72 h 
post-injection (not shown). We previously observed 
that ICL1-9 induces β2AR internalization over time in 
a HEK 293 cell receptor overexpression model [11]; 
therefore, we performed radioligand binding analysis 
to determine whether downregulation of β2AR from 
cardiac membranes occurs in response to the 
long-lasting presence of ICL1-9 in the heart. Neither 
β1AR nor β2AR densities were altered by ICL1-9 
compared to scrambled pepducin control (Scr) 24 h 
after injection (Figure 1B). Together, these data 
suggest that ICL1-9 may be capable of imparting 
effects in the heart that last hours to days, well within 
the timeframe in which cardiac damage occurs in 
response to acute ischemic injury. Thus, to determine 
whether ICL1-9 administration confers protection 
against acute ischemic injury, wild-type C57Bl6/J 
(WT) mice were given intramyocardial injections of 
either Scr or ICL1-9 pepducin followed by 30 min 
ischemia and 24 h reperfusion (I/R), after which the 
hearts were excised and infarct size assessed (Figure 
1C). Although there was no difference in the area at 
risk (AAR) between the Scr and ICL1-9 groups 
(Figure 1D), ICL1-9-treated mice had a decreased 
infarct size within the AAR (Figure 1E), 
correspondingly decreased cardiomyocyte death 
within the AAR (Figure 1F) and reciprocally 
enhanced cardiac contractility (Figure 1G).  
ICL1-9-mediated cardioprotection requires 
β2AR and β-arrestins 
Since we previously demonstrated that 
ICL1-9-induced changes in isolated adult 
cardiomyocyte function were dependent upon β2AR 
and βarr expression [11], we tested their requirement 
for relaying the protective effect of ICL1-9 against I/R 
in vivo. Cardiac AAR and infarct area values in 
response to I/R were not statistically different 
between the various KO mice and their WT controls 
treated with Scr pepducin. However, in contrast to 
WT mice, intracardiac injection of ICL1-9 was unable 
to reduce infarct size or improve cardiomyocyte 
survival within the AAR in β2ARKO mice (Figure 
2A-E). Similarly, ICL1-9 was unable to impart 
protection against I/R in either βarr1KO or βarr2KO 
mice as compared to WT control mice (Figure 2F-J). 
Therefore, direct intracardiac administration of 
ICL1-9 imparts protection against I/R-induced 
cardiomyocyte death to attenuate the acute loss of 
contractile function via βarr-dependent β2AR 
signaling.  
ICL1-9 relays improvements in cardiac 
remodeling and function after I/R 
We next sought to determine whether the acute 
cardioprotection offered by ICL1-9 translated to 
improvements in cardiac structure and function 
following I/R. WT mice that received intracardiac 
injection of Scr of ICL1-9 pepducin at the time of 
either sham or I/R surgery were monitored via 
echocardiography for up to 4 weeks (Figure S1, Table 
1 and Table 2). Analysis of LV internal diameter and 
volume indicated that ICL1-9-treated hearts displayed 
progressively less post-I/R dilation than Scr-treated 
hearts over time (Table 1). However, 
ICL1-9-mediated improvements in both fractional 
shortening and ejection fraction occurred only at early 
post-I/R timepoints, whereas Scr pepducin-treated 
hearts were able to recover contractile function by the 
end of 4 weeks. This long-term functional recovery to 
I/R is similar to that observed in previous studies 
using the same conditions of I/R [12, 14, 15]. Notably, 
wall thicknesses were unchanged between Scr- and 
ICL1-9 pepducin-treated groups (Table 2). Indeed, 
gravimetric analysis showed similar changes in size of 
the Scr- and ICL1-9-treated hearts at 4 weeks post-I/R 
(Figure 3A), and wheat germ agglutinin staining 
demonstrated similar cardiomyocyte cross sectional 
area changes in response to I/R regardless of 
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pepducin treatment (Figure 3B-C). Although ICL1-9 
treatment did not influence cardiac hypertrophy, it 
conveyed a dramatic impact on fibrosis. Masson 
Trichrome staining revealed a significantly reduced 
fibrotic infarct scar area in ICL1-9-treated hearts as 
compared to the Scr pepducin control at 4 weeks 
post-I/R (Figure 3D-E), which likely reflects the 
decreased cardiomyocyte death imparted by ICL1-9 
immediately following I/R. These results 
demonstrate that the acute cardioprotective effect of 
even a single administration of ICL1-9 at the time of 
I/R is sufficient to relay long-term benefits on cardiac 
remodeling. 
 
ICL1-9 protects against cardiomyocyte death 
in vitro 
Beyond a requirement for β2AR and either βarr1 
or βarr2, the mechanism by which ICL1-9 promotes 
cardiomyocyte survival is unknown. We previously 
demonstrated that ICL1-9 increases the 
phosphorylation of EGFR and ERK1/2 in HEK 293 
cells [11] and that βAR-mediated transactivation of 
EGFR and downstream engagement of ERK1/2 and 
Akt provides protection against cardiomyocyte death 
in vitro [4]; thus, we hypothesized that this pathway 
would be responsible for relaying the protective 
effects of ICL1-9. In order to investigate the 
 
Figure 1. ICL1-9 attenuates cardiac injury after I/R. (A) WT mice received an intracardiac injection of unlabeled ICL1-9 or TMR-conjugated ICL1-9 (red). Representative 
heart sections from at least 4 independent mice per timepoint. Sections were stained with troponin I (TNNI, green) to identify cardiomyocytes and DAPI (blue) to label nuclei. 
n=4 ICL1-9 (Unlabeled), n=5 ICL1-9TMR at each timepoint. (B) Radioligand binding analysis of βAR isoform expression in the LV of WT mice 24 h after intracardiac injection 
of Scr or ICL1-9 pepducin. n=5 Scr, n=6 ICL1-9, no significant differences observed, two-tailed unpaired t-test for each isoform. (C) Representative Evan’s Blue/TTC staining of 
hearts from mice receiving Scr or ICL1-9 pepducin injection followed by 30 min ischemia/24 h reperfusion (I/R). Quantification of (D) the area at risk (AAR) expressed as a 
percentage of the total LV area and (E) infarct size expressed as a percentage of the area at risk. n=9 each, * p < 0.05, two-tailed unpaired t-test. (F) Representative TUNEL 
staining (red) from the AAR of hearts injected with ICL1-9 or Scr control pepducin prior to I/R. Sections were counterstained with troponin I (TNNI, green) to identify 
cardiomyocytes and DAPI (blue) to label nuclei and are quantified as a percentage of the TUNEL-positive cardiomyocytes in (G). n=9 each, * p < 0.05, two-tailed unpaired t-test. 
(H) LV fractional shortening (FS) was measured at the short axis from M-mode using VisualSonics Analysis software. n=6 Scr Sham, n=6 ICL1-9 Sham, n=9 Scr I/R, n=10 ICL1-9 
I/R, *** p < 0.001, two-way repeated measures ANOVA with Bonferroni post test. 
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mechanism responsible for the protective effects of 
ICL1-9, we employed primary neonatal rat ventricular 
myocytes (NRVM), which we initially treated with 
ICL1-9 for increasing timepoints, to determine 
whether it impacts βAR membrane density in 
cardiomyocytes in vitro. Treatment of NRVM for 
either 1 h (Figure 4A) or 24 h (Figure 4B) with ICL1-9 
did not reduce membrane density of either β1AR or 
β2AR, although decreased β1AR density in response 
to ISO was detected at both timepoints. These data 
recapitulate our in vivo data, suggesting that ICL1-9 
may be capable of imparting long-lasting effects via 
regulation of membrane-localized β2AR in 
cardiomyocytes. 
 
 
Figure 2. ICL1-9-mediated protection against I/R-induced injury is β2AR- and β-arrestin-dependent. Representative images of hearts from WT controls versus 
β2ARKO (A) or βarr1KO and βarr2KO (F) mice that received Scr or ICL1-9 pepducin at the time of I/R, stained with Evan’s Blue/TTC 24 h following I/R injury. Quantification 
of (B, G) the area at risk (AAR) expressed as percentage of the total LV area and (C, H) infarct size expressed as a percentage of the AAR for WT controls versus β2ARKO 
(B-C) or βarr1KO and βarr2KO (G-H) mouse hearts. Representative TUNEL staining (red) within the AAR of WT controls versus β2ARKO (D) or βarr1KO and βarr2KO 
(I) mouse hearts. Hearts were counterstained for troponin I (TNNI, green) to label cardiomyocytes and DAPI (blue) to identify nuclei. Quantification of TUNEL+ cardiomyocytes 
expressed as a percentage of the total number of cardiomyocytes for WT versus β2ARKO (E) or βarr1KO and βarr2KO (J) mouse hearts. For (A-E): n=7 Scr WT, n=7 ICL1-9 
WT, n=10 Scr β2ARKO, n=11 ICL1-9 β2ARKO. For (F-J): n=18 Scr WT, n=10 ICL1-9 WT, n=10 Scr βarr1KO, n=10 ICL1-9 βarr1KO, n=11 Scr βarr2KO, n=10 ICL1-9 
βarr2KO. * p < 0.05, ** p < 0.01, one-way ANOVA with Tukey’s multiple comparison test. 
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Figure 3. ICL1-9 reduces fibrotic remodeling following I/R. Cardiac remodeling responses to Scr or ICL1-9 pepducin were assessed via gravimetric and 
immunohistological analyses 4 weeks post-I/R. (A) Quantification of gravimetric analysis of heart weight normalized to tibia length. n=8 Sham Scr, n=8 Sham ICL1-9, n=12 I/R Scr, 
n=11 I/R ICL1-9, ns = not significant, ** p < 0.01, one-way ANOVA with Tukey’s multiple comparison test. (B) Representative wheat germ agglutinin (WGA) staining of hearts 
to assess cardiomyocyte cross sectional area. (C) Quantification of cardiomyocyte size from WGA-stained hearts. n=7 Scr Sham, n=8 ICL1-9 Sham, n=12 Scr I/R, n=11 ICL1-9 
I/R, ns = not significant, * p < 0.05, one-way ANOVA with Tukey’s multiple comparison test. (D) Representative Masson trichrome staining of Scr or ICL1-9 pepducin-injected 
hearts following I/R injury. (E) Quantification of fibrosis from Masson trichrome-stained hearts, expressed as a percentage of the total LV area. n=8 Sham Scr, n=8 Sham ICL1-9, 
n=10 I/R Scr, n=10 I/R ICL1-9, ns = not significant, ** p < 0.01, *** p < 0.001, one-way ANOVA with Tukey’s multiple comparison test.  
 
Table 1. Echocardiographic contractile measurements 
  LV 
Volume-systolic 
(μL) 
LV 
Volume-diastolic 
(μL) 
LVID-systolic 
(mm) 
LVID-diastolic 
(mm) 
Ejection 
Fraction (%) 
Fractional 
Shortening 
(%) 
Cardiac 
Output 
(mL/min) 
Stroke 
Volume (µL) 
Heart Rate 
(BPM) 
Scr Sham Baseline 18.7±1.9 50.7±2.7 2.39±0.11 3.49±0.08 65.1±1.9 33.8±1.2 15.2±0.9 33.4±1.7 460±9 
n=16 1 d 17.7±1.8 45.4±2.3 2.33±0.11 3.32±0.10 60.2±1.9 33.6±1.0 16.3±1.5 26.9±1.2 527±15 
 3 d 17.2±1.4 49.3±1.6 2.35±0.11 3.47±0.03 63.2±2.4 33.5±1.1 14.7±1.6 32.0±1.1 455±34 
 7 d 18.2±1.1 50.7±2.3 2.34±0.05 3.41±0.07 64.1±1.2 34.2±0.8 16.6±1.0 32.9±1.6 506±15 
 14 d 20.6±1.2 54.8±2.4 2.46±0.06 3.58±0.06 62.6±1.0 33.2±0.7 16.9±0.8 34.1±1.4 493±8 
 21 d 20.3±1.4 57.5±2.6 2.49±0.07 3.58±0.07 65.0±1.3 34.9±1.0 18.9±0.8 37.3±1.5 507±9 
 28 d 20.7±2.0 56.5±2.9 2.50±0.09 3.57±0.07 63.2±1.6 31.6±1.8 18.5±0.7 35.8±1.1 514±9 
Scr I/R Baseline 21.4±1.2 56.1±2.1 2.47±0.07 3.56±0.07 63.2±1.2 33.7±1.0 15.2±0.8 34.2±1.5 443±10 
n=19 1 d 31.1±2.7 58.0±3.4 2.96±0.10 3.70±0.10 40.4±1.7 19.5±0.9 12.0±0.6 24.5±1.1 485±11 
 3 d 24.8±3.6 49.4±8.1 2.74±0.18 3.43±0.25 41.2±3.1 19.2±1.4 11.8±1.4 23.5±2.8 501±7 
 7 d 40.6±3.5 73.8±4.7 3.20±0.13 3.99±0.11 44.1±2.5 22.0±1.5 15.4±0.9 31.4±2.1 489±12 
 14 d 37.8±4.7 73.6±5.5 3.04±0.15 3.95±0.14 50.8±2.1 25.2±1.2 16.9±0.9 34.9±2.1 507±10 
 21 d 55.0±0.5 90.4±11.5 3.68±0.29 4.13±0.34 46.4±4.6 24.6±2.6 18.3±0.9 35.4±2.0 518±9 
 28 d 59.5±3.3 105.7±14.7 3.76±0.33 4.31±0.23 51.1±4.2 24.3±2.5 21.3±1.8 40.9±2.8 512±12 
ICL1-9 Sham Baseline 20.2±1.9 53.9±2.2 2.60±0.12 3.75±0.06 64.9±2.4 34.8±1.1 16.0±0.7 35.3±1.4 451±9 
n=16 1 d 20.4±1.7 49.6±3.0 2.64±0.20 3.47±0.12 59.0±2.4 32.4±1.0 15.5±2.3 28.9±2.1 477±16 
 3 d 16.1±1.2 45.2±2.6 2.25±0.05 3.37±0.09 63.7±0.8 33.7±0.4 13.2±0.7 29.1±1.6 456±2 
 7 d 23.5±1.2 58.9±1.1 2.67±0.08 3.71±0.05 62.0±1.2 32.9±0.8 19.2±0.8 38.5±0.9 498±15 
 14 d 22.9±1.2 57.8±1.9 2.53±0.06 3.67±0.07 63.3±1.0 34.0±0.7 19.6±1.2 38.0±1.4 498±15 
 21 d 24.9±3.5 60.3±4.5 2.69±0.12 3.67±0.10 58.9±2.8 31.0±1.4 18.5±1.1 35.3±2.0 525±16 
 28 d 23.4±1.6 62.3±2.8 2.60±0.07 3.73±0.07 60.3±1.5 32.9±0.9 19.8±0.6 38.3±1.6 520±10 
ICL1-9 I/R Baseline 19.4±1.3 50.8±1.9 2.64±0.09 3.46±0.07 64.4±1.8 33.7±1.1 14.6±0.5 33.6±0.9 438±9 
n=17 1 d 30.1±3.1 51.7±3.5 2.89±0.12 3.45±0.11 48.4±2.1* 23.6±1.3 12.4±0.8 24.4±1.1 478±12 
 3 d 27.8±3.3 56.1±4.4 2.72±0.10 3.54±0.14 49.0±1.8* 24.3±1.1* 14.0±1.0 28.2±2.2 499±13 
 7 d 27.7±2.0* 64.0±3.2 2.68±0.07* 3.80±0.08 55.3±1.4*** 28.5±0.9*** 17.6±0.5 34.9±1.3 515±5 
 14 d 28.3±1.7 63.7±2.6 2.80±0.08 3.80±0.07 55.4±1.5 28.5±1.0 17.7±1.0 37.1±2.0 491±10 
 21 d 29.1±4.2*** 69.9±6.4* 2.94±0.10** 3.96±0.16 54.7±2.4 30.6±3.4* 19.6±2.0 40.8±6.0 491±29 
 28 d 37.5±3.2*** 81.3±5.5** 3.14±0.12* 4.19±0.12 53.4±1.8 27.8±1.3 22.2±1.6 43.8±3.5 512±12 
* p < 0.05, ** p < 0.01, *** p < 0.001 versus Scr I/R at same timepoint, two-way repeated measures ANOVA with Bonferroni post test.  
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Table 2. Echocardiographic wall thickness measurements 
  LVAW-syst
olic (mm) 
LVAW-diastoli
c (mm) 
LVPW-systoli
c (mm) 
LVPW-diastoli
c (mm) 
Scr 
Sham 
Baseline 1.28±0.04 0.94±0.04 1.20±0.04 0.76±0.02 
n=16 1 d 1.52±0.08 1.11±0.07 1.33±0.12 0.92±0.07 
 3 d 1.64±0.08 1.11±0.07 1.25±0.19 0.92±0.16 
 7 d 1.27±0.05 0.91±0.04 1.23±0.04 0.84±0.03 
 14 d 1.32±0.07 0.95±0.05 1.27±0.04 0.87±0.04 
 21 d 1.29±0.06 0.95±0.05 1.18±0.06 0.89±0.05 
 28 d 1.28±0.04 0.95±0.03 1.10±0.06 0.81±0.03 
Scr I/R Baseline 1.34±0.03 0.96±0.03 1.21±0.04 0.87±0.03 
n=19 1 d 1.24±0.07 1.00±0.05 1.15±0.04 0.96±0.04 
 3 d 1.57±0.12 1.28±0.16 1.21±0.06 1.05±0.11 
 7 d 1.20±0.07 0.91±0.04 1.07±0.05 0.85±0.03 
 14 d 1.28±0.07 0.96±0.05 1.15±0.06 0.86±0.03 
 21 d 1.15±0.06 0.82±0.05 1.05±0.05 0.86±0.04 
 28 d 1.19±0.07 0.92±0.05 1.10±0.06 0.81±0.04 
ICL1-9 
Sham 
Baseline 1.29±0.05 0.91±0.04 1.14±0.04 0.77±0.03 
n=16 1 d 1.40±0.06 1.01±0.05 1.18±0.05 0.90±0.05 
 3 d 1.57±0.18 1.10±0.23 1.43±0.15 0.93±0.14 
 7 d 1.51±0.06 1.15±0.05 1.30±0.043 0.90±0.03 
 14 d 1.33±0.06 0.95±0.04 1.24±0.04 0.86±0.02 
 21 d 1.30±0.07 0.99±0.07 1.12±0.03 0.86±0.04 
 28 d 1.19±0.03 0.87±0.03 1.21±0.05 0.88±0.03 
ICL1-9 
I/R 
Baseline 1.33±0.04 1.00±0.04 1.16±0.04 0.84±0.04 
n=17 1 d 1.43±0.07 1.13±0.07 1.25±0.06 1.04±0.06 
 3 d 1.43±0.16 1.17±0.12 1.41±0.08 1.05±0.07 
 7 d 1.41±0.06 1.02±0.04 1.16±0.04 0.86±0.04 
 14 d 1.34±0.08 0.94±0.04 1.09±0.05 0.84±0.03 
 21 d 1.14±0.09 0.78±0.02 1.11±0.07 0.89±0.09 
 28 d 1.29±0.06 1.01±0.05 1.12±0.05 0.78±0.05 
 
To investigate the impact of ICL1-9 on 
cardiomyocyte survival, we employed a 24 h 
serum-deprivation model of stress we previously 
used to induce NRVM death [4]. Serum deprivation of 
NRVM for 24 h increased Caspase 3/7 activity, which 
was not impacted by treatment with Scr pepducin, but 
was ablated by ICL1-9 treatment (Figure 4C). To 
determine if ICL1-9 promotes survival via EGFR, 
ERK1/2 and/or Akt signaling, serum-deprived 
NRVM were co-incubated with inhibitors of each 
pathway, including PD98059 (upstream MEK1/2 
inhibitor), LY294002 (upstream PI3K inhibitor) and 
AG1478 (EGFR inhibitor) and in each case, 
ICL1-9-mediated protection of NRVM was not 
blocked (Figure 4D). Further, we could not detect a 
significant increase in ERK1/2 or Akt 
phosphorylation at any timepoint measured after 
stimulation of either NRVM or mouse hearts with 
ICL1-9 (Figure S2), revealing that ICL1-9 does not 
engage EGFR, ERK1/2 or Akt signaling to mediate its 
cardioprotective effects in cardiomyocytes in vitro or 
in whole heart in vivo.  
ICL1-9 relays cardiomyocyte survival via RhoA 
activation  
Previous work by others demonstrated that 
GPCR-mediated pro-survival effects in cardiomyo-
cytes can be relayed via activation of RhoA [16-19]; 
thus, we tested whether ICL1-9 activates RhoA in 
cardiomyocytes. Activated RhoA (GTP-bound RhoA) 
immunoprecipitations were performed using NRVM 
treated with Scr or ICL1-9 pepducin for either 5 min 
 
 
Figure 4. ICL1-9 protects against cardiomyocyte death in vitro. 125I-cyanopindolol binding analysis of NRVM treated for 1 h (A) or 24 h (B) with Veh, ISO, Scr or ICL1-9 
pepducin (10 μM each). n=4 Veh, n=4 ISO, n=5 Scr, n=5 ICL1-9. *p < 0.05, *** p < 0.001 for β1AR density, one-way ANOVA with Tukey’s multiple comparison test. (C) Caspase 
3/7 activity was measured in NRVM subjected to 24 h with or without serum in the presence of Scr or ICL1-9 pepducin (10 µM each) with values represented as a percentage 
of no serum Veh control. n=7 Veh, n=7 Veh no serum, n=10 Scr no serum, n=10 ICL1-9 no serum. ns = not significant, ** p < 0.01, *** p < 0.001, one-way ANOVA with Tukey’s 
multiple comparison test. (D) Caspase 3/7 activity was measured in NRVM subjected to 24 h without serum in the presence of Scr or ICL1-9 pepducin (10 µM each) and 
pretreated with PD98059, LY294002 or AG1478 (10 µM each) with values represented as a percentage of Veh Scr. n=18 Veh Scr, n=20 Veh ICL1-9, n=10 PD98059 Scr and 
PD98059 ICL1-9, n=8 for all other treatment groups. ns = not significant, ** p < 0.01, *** p < 0.001, one-way ANOVA with Tukey’s multiple comparison test.  
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or 24 h, revealing significantly increased RhoA 
activation in response to ICL1-9, an effect completely 
prevented by incubation of the cells with the 
β2AR-selective inverse agonist ICI 118,551 (Figures 
5A-B). Further, RhoA activation was increased in WT 
mouse hearts 24 h following intracardiac injection 
with ICL1-9, but not Scr pepducin, an effect that was 
absent in β2ARKO mouse hearts (Figure 5C). To 
determine whether RhoA inhibition would prevent 
ICL1-9-mediated protection of cardiomyocytes from 
serum deprivation-induced cell death, we assessed 
the percentage of TUNEL-positive cardiomyocytes 
treated with ICL1-9 or Scr pepducin in the presence or 
absence of the small molecule RhoA inhibitor Rhosin. 
Indeed, while ICL1-9 decreased serum 
deprivation-induced cardiomyocyte TUNEL staining, 
incubation with Rhosin completely blocked this effect 
(Figures 6A-B), as well as prevented the 
ICL1-9-mediated reduction in caspase 3/7 activation 
(Figure 6C). 
 
 
Figure 5. ICL1-9 activates RhoA in cardiomyocytes and whole heart. RhoA activation was assessed via anti-GTP-bound RhoA pulldown in NRVM pretreated with Veh 
or 100 nM ICI 118,551 and stimulated with Scr or ICL1-9 pepducin for 5 min (A) or 24 h (B), or in left ventricular lysates of WT or β2ARKO mice 24 h after intracardiac injection 
(C). Activated RhoA (IP) was normalized to total RhoA/GAPDH (input) and expressed in histograms as fold change from Veh Scr (A-B) or WT Scr (C). For (A): n=7 Veh Scr, 
n=6 Veh ICL1-9, n=5 ICI Scr and n=6 ICI ICL1-9; for (B): n=9 Veh Scr and Veh ICL1-9, n=4 ICI Scr and ICI ICL1-9; for (C): n=14 WT Scr, n=16 WT ICL1-9, n=13 β2ARKO Scr, 
n=14 β2ARKO ICL1-9. * p < 0.05, one-way ANOVA with Tukey’s multiple comparison test.  
 
 
Figure 6. RhoA inhibition prevents ICL1-9-mediated cardiomyocyte survival. NRVM underwent serum deprivation for 24 h in the presence or absence of ICL1-9 or 
Scr pepducin with or without Rhosin (10 µM each). Cells were fixed, stained for TUNEL, DAPI and αSrA (A) and TUNEL-positive cardiomyocytes (arrowheads) were quantified 
as a percentage of total cardiomyocytes (B). n=27 Veh+Scr, Veh+ICL1-9, n=24 Rhosin+Scr, n=25 Rhosin+ICL1-9 (number of fields of view assessed from 5 plates per treatment 
and 3 independent primary NRVM isolations). ns = not significant, * p < 0.05, one-way ANOVA with Tukey’s multiple comparison test. (C) Caspase 3/7 activity was measured 
in NRVM subjected to 24 h without serum in the presence of Scr or ICL1-9 pepducin (10 µM each) and pretreated with Rhosin (10 µM) with values represented as a percentage 
of Veh Scr. n=9 Veh Scr, n=8 for all other groups. ns = not significant, * p < 0.05, one-way ANOVA with Tukey’s multiple comparison test.  
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ICL1-9 reduces 
hypoxia/reoxygenation-induced caspase 
activation and mitochondrial superoxide 
formation via RhoA/ROCK activation in 
cardiomyocytes  
 Since acute ischemic injury results in 
cardiomyocyte death due to enhanced mitochondrial 
oxidative stress [20], we sought to determine whether 
ICL1-9 acts to reduce this response. Thus, we used an 
in vitro model of hypoxia-reoxygenation (H/R, [19]) 
to mimic in vivo I/R. H/R-exposed NRVM displayed 
increased Caspase 3/7 activity (Figure 7A) and 
mitochondrial superoxide formation (Figure 7C) that 
were each significantly reduced by ICL1-9 but not Scr 
pepducin. The ICL1-9-mediated protection against 
both Caspase 3/7 activity (Figure 7B) and 
mitochondrial superoxide formation (Figure 7D-E) 
was blocked by co-incubation with either ICI 118,551 
or Rhosin. Further, since the downstream RhoA 
effector ROCK was shown previously to relay 
RhoA-dependent survival signaling [16, 19], we tested 
whether inhibition of ROCK with its small molecule 
inhibitor Y-27632 would prevent ICL1-9-mediated 
pro-survival effects. Indeed, the ICL1-9-mediated 
protection against both Caspase 3/7 activity (Figure 
7B) and mitochondrial superoxide formation (Figures 
7D-E) was blocked by co-incubation with Y-27632. 
Altogether, our study shows for the first time that 
direct administration of a β-arrestin-biased 
β2AR-selective pepducin promotes cardiomyocyte 
survival via RhoA/ROCK activation to prevent 
adverse cardiac remodeling in response to acute 
ischemic injury. 
 
 
Figure 7. ICL1-9 decreases H/R-induced caspase 3/7 activity and superoxide formation in cardiomyocytes via RhoA/ROCK activation. NRVM underwent 
hypoxia for 4 h followed by reoxygenation for 20 h in the presence of Veh, Scr or ICL1-9 pepducin (10 µM each) with or without pretreatment with ICI 118,551 (100 nM), 
Y-27632 (10µM) or Rhosin (10 µM). Caspase 3/7 activity (A-B) was assessed as in Figure 5 and superoxide formation (C-D) was measured using mitosox red. Values are 
expressed as a percentage of H/R Veh (A, C) or Veh Scr (B, D). For (A): n=9 for all treatment groups, for (B): n=12 for all treatment groups, for (C): n=8 Veh and H/R Veh, 
n=14 H/R Scr and H/R ICL1-9, for (C): n=14 for Veh Scr and Veh ICL1-9, n=8 for all other treatment groups. ns = not significant, * p < 0.05, *** p < 0.001, one-way ANOVA with 
Tukey’s multiple test. (E) Representative images of mitoSOX staining (red) in NRVM with or without H/R (left panels) or H/R plus Veh, ICI 118,551 (100 nM), Y-27632 (10µM) 
or Rhosin (10 µM) and Scr or ICL1-9 pepducin (10 µM each, right panels). Cells were counterstained with DAPI (blue) to detect nuclei. n=5 for Veh No H/R and Veh H/R, n=6 
for Veh H/R Scr and Veh H/R ICL1-9, n=4 for all other H/R treatment groups. 
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Discussion 
Targeting GPCRs to treat I/R-induced cardiac 
injury has been a mainstay of therapeutic research for 
decades. The activation or inhibition of numerous 
cardiac GPCRs, including adenosine, adrenergic, 
apelin, formyl peptide, opioid, relaxin, sphingosine 1 
phosphate and urocortin receptors, have been 
investigated for their potential cardioprotective 
effects following I/R-induced injury [17, 21-29]. 
Recently, research efforts have focused more precisely 
on harnessing the potential of biased signaling, 
wherein distinct proximal signaling branches of 
GPCRs, such as G protein- versus βarr-dependent 
pathways, may be engaged to promote 
cardioprotection. For instance, recent work described 
the impact of a formyl peptide receptor (FPR) ligand 
that acts in a biased manner to promote ERK1/2- and 
Akt-associated survival signaling with reduced 
pro-death Ca2+ signaling, which conferred greater 
improvement in post-I/R outcomes in vivo compared 
to a conventional FPR ligand [23]. With regard to 
βarr-dependent signaling, it has been known for some 
time that βAR stimulation relays pro-survival effects 
via engagement of βarr [5, 30] and, therefore, may 
represent a novel therapeutic pathway to mitigate 
I/R-induced myocyte death; however, the ability to 
promote this pathway with orthosteric ligands to test 
this theory in vivo has been challenging. Here, we 
demonstrate for the first time that pepducin-mediated 
allosteric modulation of β2AR engages 
βarr-dependent cardioprotection against acute 
I/R-induced injury in vivo to relay structural and 
functional benefits. Thus, this signaling paradigm 
represents a bona fide therapeutic strategy to promote 
cardiac survival signaling at the time of I/R injury. 
We previously demonstrated that ICL1-9 
enhanced the activation of known survival signaling 
pathways in a βarr1- and βarr2-sensitive manner in a 
HEK 293 cell model with heterologous overexpression 
of β2AR, and that ICL1-9 could increase isolated adult 
cardiomyocyte contractility, which was dependent 
upon endogenous expression of β2AR and sensitive to 
the deletion of either βarr1 or βarr2 [11]. These results 
suggested that ICL1-9 may be capable of engaging 
pro-survival signaling in vivo to relay protection 
against I/R-induced myocyte death via an 
endogenous βarr-dependent β2AR pathway. Our 
current study confirms this paradigm as ICL1-9 was 
unable to reduce infarct size and cardiomyocyte death 
in response to I/R in mice lacking expression of β2AR, 
βarr1 or βarr2. With regard to these genetic mouse 
models, we observed that β2ARKO mice are as 
susceptible to I/R-induced injury as WT mice, which 
aligns with previous studies demonstrating that 
β2ARKO mice are not protected, or are even more 
susceptible to injury and death, from either 
permanent coronary ligation-, catecholamine- or 
anthracycline-induced cardiac toxicity [6, 31, 32]. 
However, in contrast to a recent study in which 
βarr2KO mouse hearts experienced less damage 
following I/R than WT hearts [33], in our study 
neither βarr1KO nor βarr2KO mice exhibited a 
statistically significant difference in I/R-induced 
injury compared to WT mice. Notably, the authors of 
the previous study modeled I/R using an ex vivo 
Langendorff perfusion system in which they could 
assess readouts of cardiac damage only at early 
timepoints (minutes to hours), while our in vivo 
assessment occurred 24 h post-I/R in vivo. In 
addition, others have reported that βarr1KO mice 
exhibit less cardiac cell death 24 h post ischemic injury 
[34], though infarct sizes and function were not 
assessed at this timepoint and the study employed 
permanent coronary ligation, making comparisons 
between the models difficult. Regardless of these 
disparate outcomes with regard to the potential 
impact of isoform-selective deletion of βarr on the 
response to acute ischemic injury, we definitively 
show here that the ability of ICL1-9 to relay acute 
cardioprotection against I/R-induced injury in vivo 
occurs via βarr-dependent β2AR signaling since 
deletion of any one of β2AR, βarr1 or βarr2 was 
sufficient to abolish the effect.  
Previous work, including our own, has shown 
that βarr-dependent βAR signaling mediates 
cardiomyocyte survival via transactivation of EGFR 
with subsequent downstream activation of ERK1/2 
and Akt [4, 5, 35]. Since we had demonstrated that 
ICL1-9 activated EGFR and increased ERK1/2 
phosphorylation for hours in a HEK 293 cell model 
[11], we postulated that its cardioprotective effect 
against I/R would be relayed via this mechanism. 
However, we were unable to detect a significant 
increase in phosphorylation of either ERK1/2 or Akt 
at multiple timepoints following treatment of primary 
cardiomyocytes or injection of mouse hearts with 
ICL1-9. Further, antagonists of EGFR, ERK1/2 and 
Akt signaling pathways were completely unable to 
prevent ICL1-9-mediated protection against 
pro-death caspase 3/7 activation in NRVM 
undergoing serum deprivation. However, GPCR 
signaling paradigms characterized in HEK 293 cell 
models do not necessarily translate to those used in 
cardiomyocytes, possibly due to factors including 
distinct expression and localization patterns of the 
GPCRs themselves or their downstream signaling 
components [4, 36].  
Therefore, an unrecognized βarr-dependent 
molecular pathway was responsible for promoting 
cardiomyocyte survival downstream of β2AR, which 
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we postulated to be mediated via RhoA activation 
based on the following lines of evidence: 1) previous 
work by Brown and colleagues detailed the ability of 
RhoA to promote cardiomyocyte survival, either via 
cardiomyocyte-specific low-level expression of 
constitutively active RhoA or in response to 
sphingosine-1-phosphate (S1P) stimulation of the S1P 
receptor 3 [17-19]; 2) several studies, albeit in HEK 293 
cells, have shown that angiotensin type 1A 
receptor-mediated regulation of RhoA activity is 
βarr-sensitive [37-39]; and 3) β2AR stimulation was 
shown to induce βarr2-dependent membrane 
translocation of p115RhoGEF and subsequent 
activation of RhoA, also in HEK 293 cells [40]. Thus, 
we tested whether ICL1-9-mediated pro-survival 
effects in cardiomyocytes were sensitive to inhibition 
of RhoA. Indeed, treatment with ICL1-9 induced 
activation of RhoA in cardiomyocytes and in whole 
heart, and, although we had not detected an 
ICL1-9-mediated increase in ERK1/2 or Akt 
phosphorylation at any timepoint, RhoA activation 
occurred rapidly and was sustained for at least 24 h 
both in vitro and in vivo. This activation was essential 
to the promotion of cardiomyocyte survival since 
inhibition or deletion of β2AR prevented 
ICL1-9-mediated RhoA activation and protection 
from ischemia in response to H/R in vitro or I/R in 
vivo. Further, although the exact biochemical nature 
by which pepducins induce signaling at their 
receptors remains elusive [41], Rhosin-mediated 
inhibition of RhoA activation by ICL1-9 is consistent 
with βarr-dependent regulation of a RhoGEF since 
Rhosin directly targets the RhoGEF binding domain 
of RhoA [42], though the RhoGEF in question remains 
to be identified in future studies. We additionally 
observed that inhibition of the RhoA effector ROCK 
also prevented ICL1-9-mediated pro-survival effects 
in cardiomyocytes, consistent with other reports [16, 
19], though the molecular determinants downstream 
of ROCK remain to be identified in future studies. In 
all, our data supports a mechanism by which 
βarr-biased β2AR stimulation leads to prolonged 
activation of RhoA to confer cardioprotection against 
ischemic injury.  
 An additional unexpected observation in our 
study was the lack of β2AR downregulation induced 
by ICL1-9 treatment. We had previously shown in 
HEK 293 cells that ICL1-9 caused β2AR 
internalization [11]; however, in both isolated 
cardiomyocytes and in whole heart, ICL1-9 did not 
alter β2AR levels, even though the canonical 
non-selective βAR agonist ISO was able to reduce the 
level of β1AR after stimulation. Since ICL1-9 acted as 
a partial agonist for internalization in the HEK 293 cell 
model with β2AR overexpression [11], this result 
could be due to an undetectable or negligible loss of 
endogenous levels of cardiac β2AR, which others 
have recently shown to be expressed at low or 
sporadic levels in adult cardiomyocytes [43]. 
Alternatively, the allosteric modulation of β2AR by 
ICL1-9 in cardiomyocytes may result in the 
engagement of a conformation of βarr that 
preferentially promotes pro-survival signaling over 
time at the expense of appreciable receptor loss. This 
notion would fit with current interpretations of 
GPCR-βarr interaction wherein specific intracellular 
phosphorylation residues on the receptor are 
differentially induced by distinct ligands/ 
modulators, which in turn promote unique 
βarr-assembled scaffolds [44, 45]. Thus, ICL1-9 likely 
induces a preference for a distinct β2AR-dependent 
βarr signaling module in cardiomyocytes that 
includes a RhoGEF, as discussed above, rather than 
components of endocytic machinery. Further, ICL1-9 
localization within the heart and cardiomyocytes for 
at least 24 h after treatment, corresponding with 
sustained activation of RhoA and decreased cell 
death, offers an explanation as to how a single 
intramyocardial injection of ICL1-9 at the time of I/R 
led to both immediate improvements in cardiac 
function and decreased fibrotic remodeling over time. 
Thus, ICL1-9 acts primarily to maintain 
cardiomyocyte survival through reperfusion/ 
reoxygenation, thereby leading secondarily to 
improvements in cardiac function and fibrotic 
remodeling. Future studies should address whether 
single or repeated administrations of ICL1-9 after 
injury offers further functional benefit, or if the 24 h 
post-I/R window is the only timeframe in which it 
can relay its benefits via acute cardiomyocyte 
retention.  
Until now the in vivo, and even early clinical, 
use of pepducins has been focused on those targeting 
GPCRs expressed in easily accessible cells and 
compartments, including platelets and the liver, in 
which intravenous administration of pepducins 
results in sufficient uptake into the desired tissues [8, 
46, 47]. As such, a potential limitation of the use of 
ICL1-9 in particular for prevention of cardiac injury is 
its method of delivery. In this study we used direct 
intramyocardial injections to allow the greatest 
accumulation of the pepducin within the 
myocardium, which diffused away from the injection 
site over time, ultimately enhancing cardiomyocyte 
survival in response to I/R. However, the ability of 
ICL1-9 to diffuse from the bloodstream through the 
endothelial cell layer and into the cardiac muscle 
following intracoronary delivery at the time of 
reperfusion, and its resulting efficacy in comparison 
to direct intramyocardial injection, is as yet untested. 
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Thus, development of small molecules to allosterically 
promote βarr-dependent β2AR signaling in a similar 
fashion to ICL1-9 could offer an improved approach 
for a more generalized systemic delivery. Regardless, 
this study shows for the first time that allosteric 
engagement of βarr-biased β2AR signaling via 
pepducin administration at the time of ischemic 
injury in vivo promotes cardiomyocyte survival, 
thereby relaying structural and functional benefits, 
and represents a desirable and specific therapeutic 
target for cardioprotection. 
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